Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome

Fecha
2021-08-24
Autores
Profe guía
Perfil ORCID
https://orcid.org/0000-0001-8154-8550
 https://orcid.org/0000-0002-8341-7658
 https://orcid.org/0000-0002-7140-4294
 https://orcid.org/0000-0001-6999-4099
 https://orcid.org/0000-0001-5567-3374
 https://doi.org/10.1111/codi.15899
Título de la revista
ISSN de la revista
Título del volumen
Editor
Wiley
ISBN
ISSN
1463-1318
ISSNe
DOI
URI
http://hdl.handle.net/20.500.12254/2157
Resumen
Aim: Minimal residual disease (MRD) is the net result of the biological properties of disseminated tumour cells and the effect of the immune system and treatment to eliminate them. The aim of this work is to report the changes in MRD status and immune function (lymphocyte count) after FOLFOX chemotherapy, and the outcome in Stage III colon cancer patients. Method: This study is a prospective, single-centre observational study. Lymphocyte counts were determined prior to and 1, 2 and 3 months after the completion of chemotherapy. Circulating tumour cells (CTCs) and bone marrow micrometastases were determined using immunocytochemistry with anticarcinoembryonic antigen prior to and 1 month after chemotherapy. MRD was classified as negative (Group I), micrometastasis positive only (Group II) and CTC positive (Group III). Changes in lymphocyte counts and MRD subtype following chemotherapy and relapse-free progression were analysed. Results: Of the total of 185 patients, 83 (44.9%) relapsed. The risk of relapse significantly increased from Groups I to III (p < 0.001) and with decreasing lymphocyte count (p < 0.01). The lymphocyte count significantly decreased from Groups I to III (p < 0.001). Multivariance Cox regression analysis showed hazard ratios of 3.58 (Group II), 17.43 (Group III) and 0.39 (lymphocyte count) in predicting relapse. Following chemotherapy, improved lymphocyte count was associated with improved MRD subtype (p < 0.0001). Neither baseline lymphocyte count nor MRD subtype predicted response to chemotherapy. Five-year relapse-free survival for combined lymphocyte–MRD subtypes was 95%, 57% and 5% for Groups I to III, respectively (p < 0.001). Conclusion: Following chemotherapy, improvements in immune function were associated with improved MRD subtype and a better relapse-free survival.
Descripción
Lugar de Publicación
Sponsorship
Citación
Murray NP, Villalon R, Hartmann D, Rodriguez MP, Aedo S. Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome. Colorectal Dis. 2021;00:1–15. https:// doi.org/10.1111/codi.15899
Palabras clave
Licencia
Atribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
Licencia URL
http://creativecommons.org/licenses/by-nc-sa/3.0/cl/
Colecciones
Artículos de Revistas